Clinical trials: CMV Infection
CMV
Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer Therapy
Cytomegalovirus (CMV) is the most common member of the herpes viruses to infect humans. Its double-stranded linear DNA duplex contains 165 genes that encode viral proteins that mimic and interact with human cellular proteins and…
- Trial name
- CMV-ICU (NCT04280380)
- Testing
- Real time PCR
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fundación de investigación HM
Cytomegalovirus Infections
CMV Infection in Adolescent Males
The purpose of this study is to find out more about cytomegalovirus (CMV) and how it is spread between people. One thousand adolescent males ages 12-17 years will participate in this study.
- Trial name
- NCT00302029
- Where
- 3 sites in United States
- Volunteers
- 411 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
CMV Colitis
Stool and Serum CMV-PCR in Diagnosing CMV Colitis
CMV viral load detected by real-time polymerase chain reaction (PCR) in either serum or stool may be beneficial in diagnosing CMV colitis, but the data is limited.
- Trial name
- NCT05522283
- Testing
- Stool and blood CMV PCR
- Where
- Thailand
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Mahidol University
HIV I Infection
To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity of VIR 1388 in adults in good health without HIV.
- Trial name
- NCT05854381
- Testing
- VIR-1388
- Where
- 10 sites in United States, South Africa
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus (CMV), HIV (Human Immunodeficiency Virus)
A Clinical Study to Evaluate the Safety and Immunogenicity of a Higher Dose of the Study Vaccine, VIR-1388, in HCMV-seropositive Adult Participants Without HIV
This study is to test an experimental HIV Vaccine. About 12 participants, aged 18-55 years and who already have cytomegalovirus (CMV) will take part in this study.
- Trial name
- NCT07801456
- Testing
- VIR-1388
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV I Infection
VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers
This is a Phase 1a, first in human study in which healthy adult participants who are considered to be at low-risk for HIV infection and are seropositive for cytomegalovirus (CMV) will receive two doses of VIR-1111 or placebo.
- Trial name
- NCT04725877
- Testing
- VIR-1111
- Where
- 3 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Vir Biotechnology, Inc.
Cytomegalovirus Infections
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
The purpose of this study is to assess the safety, reactogenicity and immune response of the candidate CMV recombinant protein subunit (CMVsu) vaccine consisting of a combination of glycoproteins B (gB) and pentamer antigens…
- Trial name
- NCT05089630
- Testing
- Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine
- Where
- 18 sites in United States
- Volunteers
- 333 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Response of Older Adults to Influenza Vaccination With Regard to Cytomegalovirus (CMV) Status
The study is being undertaken to evaluate responses to seasonal influenza vaccine in older adults with respect to their CMV status.
- Trial name
- CMVflu (NCT00442975)
- Testing
- Fluarix
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Public Health England
Nonneoplastic Condition
Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants
RATIONALE: Vaccines made from peptides may help the body build an immune response to kill cytomegalovirus. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in preventing cytomegalovirus in…
- Trial name
- NCT00722839
- Testing
- PADRE-CMV fusion peptide vaccine, tetanus-CMV fusion peptide vaccine, agatolimod sodium
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Cytomegalovirus Infection
Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV
The objectives of this first-in-human is to evaluate the safety and the immunogenicity of three administrations of a bivalent vaccine candidate against human cytomegalovirus, at three different dose levels.
- Trial name
- NCT02798692
- Testing
- Low dose HB-101, Medium dose HB-101, High dose HB-101
- Where
- Belgium
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Hookipa Biotech GmbH
Acute Bacterial Infections, Acute Viral Infections
300 Antibody Diagnostic Test Kit
For the development of a Point of Care IVD test kit for acute phase disease detection against a variety of bacterial and viral infections.
- Trial name
- Antibody 300 (NCT01646411)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The Plasma Source
Cytomegalovirus Infection
Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM
Objectives of this trial are to: 1. Evaluate the kinetics and magnitude of the CMV-specific immune response post-Towne challenge (3000 pfu) in healthy CMV-seronegative volunteers who received VCL CT02 administered ID or IM 9 to…
- Trial name
- NCT00370006
- Testing
- Towne CMV vaccine
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Cytomegalovirus Infections
A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)
AVX601, a bivalent alphavirus replicon vaccine expressing three CMV proteins (gB, pp65 and IE1) is a candidate vaccine against cytomegalovirus (CMV).
- Trial name
- CMV (NCT00439803)
- Testing
- AVX601
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AlphaVax, Inc.
CMV Infection, EBV Infection
Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT
To evaluate the safety and tolerability of partial HLA-matched VSTs against both CMV and EBV viruses in recipients of allogeneic hematopoietic stem cells with refractory viral infections (CMV and/or EBV).
- Conditions
- CMV Infection, EBV Infection, Stem Cell Transplant
- Trial name
- NCT06075927
- Testing
- Virus specific T cells
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Cytomegalovirus Infections, Pregnancy
Clinical Trial of Behavioral Modification to Prevent Congenital Cytomegalovirus
The purpose of this study is to develop a brief screening and behavioral intervention for the prevention of congenital cytomegalovirus (CMV) that will both be acceptable to clinic staff and feasible to implement as part of…
- Conditions
- Cytomegalovirus Infections, Pregnancy, Behavior
- Trial name
- CDC/CMV (NCT01819519)
- Testing
- Educational Intervention
- Where
- United States
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- Women and Infants Hospital of Rhode Island
Cytomegalovirus Infection
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety and reactogenicity of mRNA-1647 vaccine in all participants.
- Trial name
- NCT05085366
- Testing
- mRNA-1647
- Where
- 296 sites in United States, Australia and 11 more
- Volunteers
- 7,454 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Cytomegalovirus Infection
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
This clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647 cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years of age.
- Trial name
- NCT04232280
- Testing
- mRNA-1647
- Where
- 9 sites in United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Cytomegalovirus Infections
Recombinant CMV gB Vaccine in Postpartum Women
The purpose of this study is to determine if a new cytomegalovirus (CMV) vaccine (CMV gB/MF59) can safely prevent mothers from catching CMV infection between pregnancies.
- Trial name
- NCT00125502
- Testing
- CMV gB vaccine, MF59 adjuvant
- Where
- 2 sites in United States
- Volunteers
- 464 people, healthy volunteers welcome
- Sponsor
- Robert Pass, MD
Cytomegalovirus Infection
Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge
Objectives of this trial are to: Evaluate the kinetics and magnitude of the CMV-specific immune response post-Towne challenge (3000 pfu) in healthy CMV-seronegative volunteers who receive VCL CT02 administered (1 mg weekly x 3) 3…
- Trial name
- NCT00373412
- Testing
- VCL CT02 pDNA vaccine, Towne CMV vaccine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Blood Donors, Blood Transfusion
Transfusion Infections Pediatric Prospective Study (TRIPPS)
To conduct a prospective study of pediatric transfusion recipients to determine the risk of transmitting various infectious agents by blood transfusion.
- Conditions
- Blood Donors, Blood Transfusion, Cytomegalovirus Infections, Hepatitis, Viral, Human
- Trial name
- TRIPPS (NCT00029406)
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Naomi Luban